|
|
|
Xortx Therapeutics inc (NASDAQ: XRTX) |
|
Xortx Therapeutics inc
Officers & Directors
Allen Davidoff has served as President, Chief Executive Officer, and Director since January 9, 2018. He was previously Chief Scientific Officer and co-founder of Stem Cell Therapeutics Inc. Michael Bumby has been Chief Financial Officer since December 18, 2024, and was formerly CFO of VIVO Cannabis Inc. Stacy Evans has held the position of Chief Business Officer since November 16, 2022, with over 20 years of experience in biopharmaceutical business development. Stephen Haworth has been Chief Medical Officer since July 1, 2021, and previously served as Executive Medical Director at Cormedix Inc. and Vice President at Vaxlnnate Corporation.
Xortx Therapeutics inc currently has 15 employees.
News about Xortx Therapeutics inc Key Personnel |
XORTX Therapeutics Inc. Announces Change of Auditor Amid Financial Turbulence and Leadership ShakeupCALGARY, Alberta – XORTX Therapeutics Inc. (XORTX or the Company) has taken a significant step as part of its strategic overhaul by announcing a change of auditor. Effective January 16, 2025, the Company has transitioned from Smythe LLP, Chartered Professional Accountants, to Davidson and Company LLP, Chartered Professional Accountants, as its new auditing firm. This move comes at a time when the firm is grappling with serious financial challenges that have alarmed investors and analysts alike. Recent Financial ChallengesIn the realm of healthcare, and particularly among biotechnology firms, financial healt...
|
XORTX Therapeutics Faces Financial Headwinds as it Shifts Focus on Gout Treatment Amid Leadership ChangesIn an era marked by relentless innovation in biopharmaceuticals, XORTX Therapeutics Inc. appears to be navigating a tumultuous path. Recently, the Calgary-based company announced plans to advance its late-stage gout program aimed at patients intolerant to allopurinol, an existing and widely used medication for managing gout. However, the ambitious pivot toward this niche market comes at a time when XORTX is grappling with significant financial challenges, raising questions about its long-term viability and strategic direction.On one hand, XORTX’s renewed focus on allopurinol-intolerant gout offers a gli...
|
XORTX Therapeutics Inc. has announced a significant addition to its executive team with the appointment of Dr. Michael Bumby as Chief Financial Officer (CFO). Dr. Bumby s expertise in the pharmaceutical and biotechnology sectors aims to bolster the firm s financial strategy as it navigates a turbulent financial landscape. However, the company has faced harsh realities, with its share price plummeting by 23.53% during the fourth quarter of 2023, reflecting concerns over its financial stability.The recent financial disclosures reveal that XORTX recorded a cumulative net loss of $2 million for the 12 months ending in Q4 2023. This staggering figure corresponds to a return on investment (ROI) of -406.39%, a stri...
|
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
